Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

68.92
BATS BZX Real-Time Price
As of 3:33pm ET
 -3.17 / -4.40%
Today’s Change
55.00
Today|||52-Week Range
133.62
-36.45%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$13.9B

Company Description

Incyte Corp. is a biopharmaceutical company, which focuses on the discovery, development, development, formulation, manufacturing and commercialization of proprietary therapeutics to treat serious unmet medical needs, primarily in oncology. Its product, Jakafi, a JAK1 and JAK2 inhibitor, is currently approved in the U.S. for the treatment of intermediate or high-risk myelofibrosis and is in development as a potential treatment for other cancers. The companywas founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Contact Information

Incyte Corp.
1801 Augustine Cut-Off
Wilmington Delaware 19803
P:(302) 498-6700
Investor Relations:
(302) 498-5914

Employees

Shareholders

Mutual fund holders57.37%
Other institutional46.03%
Individual stakeholders15.98%

Top Executives

Hervé HoppenotChairman, President & Chief Executive Officer
David W. GryskaChief Financial Officer & Executive Vice President
Reid M. HuberChief Scientific Officer & Executive VP
Steven H. SteinChief Medical Officer & Senior Vice President
Eric H. SiegelSecretary, Executive VP & General Counsel